Abstract
Besides the many recognised compounds described and detailed in the present issue including the Vinca alkaloids, the taxanes, certain cryptophycines, epothilones and eleutherobines, several new products interacting with tubulin are identified regularly in the literature. These products may have been isolated from natural sources (plants, marine organisms, bacteria), but also more recently combinatorial, or at least automatised chemistry, has provided new families of small molecules, which on occasions have been found by High Throughput Screening directed against tubulin as a specific target. A recent review has listed more than one hundred of such derivatives [1]. Certain of these are in an advanced stage of pharmaceutical development, as reviewed by Li et al. [2] and von Angerer [3]. From a mechanistic point of view, these newer products may be classified into one of three main families, although exceptions to this rule are now also being reported on. microtubule stabilising compounds, Vinca alkaloid site interacting agents, colchicine site binders. This brief final contribution to this volume will focus only on the newly identified products for which active pharmaceutical development has been reported on during the last three years.
Keywords: Cryptophycines, Epothilones, Eleutherobines, vinflunine
Current Pharmaceutical Design
Title: Epilogue
Volume: 7 Issue: 13
Author(s): Jacques Fahy and Bridget T. Hill
Affiliation:
Keywords: Cryptophycines, Epothilones, Eleutherobines, vinflunine
Abstract: Besides the many recognised compounds described and detailed in the present issue including the Vinca alkaloids, the taxanes, certain cryptophycines, epothilones and eleutherobines, several new products interacting with tubulin are identified regularly in the literature. These products may have been isolated from natural sources (plants, marine organisms, bacteria), but also more recently combinatorial, or at least automatised chemistry, has provided new families of small molecules, which on occasions have been found by High Throughput Screening directed against tubulin as a specific target. A recent review has listed more than one hundred of such derivatives [1]. Certain of these are in an advanced stage of pharmaceutical development, as reviewed by Li et al. [2] and von Angerer [3]. From a mechanistic point of view, these newer products may be classified into one of three main families, although exceptions to this rule are now also being reported on. microtubule stabilising compounds, Vinca alkaloid site interacting agents, colchicine site binders. This brief final contribution to this volume will focus only on the newly identified products for which active pharmaceutical development has been reported on during the last three years.
Export Options
About this article
Cite this article as:
Fahy Jacques and Hill T. Bridget, Epilogue, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397447
DOI https://dx.doi.org/10.2174/1381612013397447 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of Mammography and Ultrasonography for Tumor Size of DCIS of Breast Cancer
Current Medical Imaging Meet Our Editorial Board Member
Current Medicinal Chemistry Mucoadhesive Chitosan Derivatives as Novel Drug Carriers
Current Pharmaceutical Design Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells
Current Molecular Medicine Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Telomeres, Genomic Instability, DNA Repair and Breast Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Editorial [Hot Topic: Towards Tailored Treatment - New Organ-Specific Drug Strategies Interfering in Signal Transduction (Guest Editors: Jai Prakash and Martin H. de Borst)]
Current Signal Transduction Therapy Biosynthesis and Biological Activities of In Vitro Derived Solasodine Glycoalkaloids from <i>Solanum laciniatum</i>
The Natural Products Journal Pathophysiology of NASH: Perspectives for a Targeted Treatment
Current Pharmaceutical Design State-of-the-Art: Exosomes in Colorectal Cancer
Current Cancer Drug Targets Molecular Factors Influencing the Affinity of Flavonoid Compounds on PGlycoprotein Efflux Transporter
Current Computer-Aided Drug Design Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Search for Distinctive Markers in DNT and Cortical Grade II Glioma in Children: Same Clinicopathological and Molecular Entities?
Current Topics in Medicinal Chemistry Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Cytotoxicity of an Ebulin l-Anti-Human CD105 Immunotoxin on Mouse Fibroblasts (L929) and Rat Myoblasts (L6E9) Cells Expressing Human CD105
Medicinal Chemistry